Filing Flows › Zomedica (ZOMDF) › Guidance & outlook

Zomedica (ZOMDF) guidance and outlook

Zomedica's 10-Q filed Nov 4, 2026 makes 12 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 4, 2026

• We assume a zero dividend yield at the date of grant, as we do not anticipate paying dividends in the foreseeable future.
• We assume a zero-dividend yield, as we do not anticipate paying dividends in the foreseeable future.
• Financial projections and long-term growth rates used for our reporting units will be consistent with, and use inputs from, our internal long-term business plan and strategies.
• We rely on various data points and assumptions, including, but not limited to, the expected volume of consumables which will be sold, anticipated growth rates, and anticipated placements.
• In general, we expect revenue to increase in subsequent periods as we increase our sales, marketing, and commercialization efforts.
• We anticipate that costs of revenue will continue to increase in subsequent periods in accordance with increased unit sales as described above.
• While we expect future general and administrative expense to increase, we expect it to decrease proportionally relative to sales and related product expansion.
• We anticipate that research and development expense will increase as we maintain and enhance our current product lines and develop new products.
• We expect future selling and marketing expense to increase in line with product expansion and growth in our commercialization efforts.
• We expect to continue to record net losses in future periods until such time as we have sufficient revenue from product sales to offset our operating expenses.
• We do not expect that our operations will require significant increases in our short-term cash needs, and our short-term cash requirements have not changed materially since the 2025 Form 10-K.
• As of September 30, 2026, we had deferred tax assets for net operating loss carryforwards for U.S. federal income tax purposes of $23,756 and non-capital loss carryforwards for Canada of $9,644, which will begin to expire in fiscal year 2035.

Zomedica's latest quarter

Questions

What does Zomedica expect?

We assume a zero dividend yield at the date of grant, as we do not anticipate paying dividends in the foreseeable future. We assume a zero-dividend yield, as we do not anticipate paying dividends in the foreseeable future. Financial projections and long-term growth rates used for our reporting units will be consistent with, and use inputs from, our internal long-term business plan and strategies.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.